Tiếp theo

Tự chạy

Targetting PD-L1 with avelumab in metastatic Merkel cell carcinoma

1 Lượt xem • 07/17/23
Đăng lại
Nhúng
administrator
administrator
Người đăng ký
0

Dr Kaufman speaks with ecancertv at ASCO 2016 to discuss the results of phase II JAVELIN Merkel 200 trial, in which patients with metastatic Merkl cell carcinoma received avelumab, a PD-L1 checkpoint inhibitor.

Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with Merkel cell polyomavirus, with limited therapeutic options after 1st-line chemotherapy.

Dr Kaufman describes the results of the JAVELIN trial in which, of a cohort of 88, six patients (9.8%) achieved complete responses, 12 (19.7%) had partial responses, and 7 (11.5%) had stable disease (83.3% responses were ongoing).

He also details the ongoing progression free survival data, and offers that additional clinical evaluation of avelumab for is warranted.

Cho xem nhiều hơn
0 Bình luận sort Sắp xếp theo
Bình luận trên Facebook

Tiếp theo

Tự chạy